Melatonin-micronutrients Osteopenia Treatment Study (MOTS)

A translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures

Sifat Maria, Mark H. Swanson, Larry T. Enderby, Frank D'Amico, Brianna Enderby, Rebekah M. Samsonraj, Amel Dudakovic, Andre J van Wijnen, Paula A. Witt-Enderby

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This one-year double blind randomized control trial assessed the effects of nightly melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7; MSDK) on bone mineral density (BMD) and quality of life (QOL) in postmenopausal osteopenic women (ages 49-75). Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3%) and left femoral neck (2.2%), with an upward trend for total left hip (p=0.069). MSDK increased serum P1NP levels and reduced bone turnover (CTx:P1NP). Psychometric analyses indicated that mood and sleep quality improved for the MSDK group. MSDK-exposed human mesenchymal stem cells (hMSCs) and human peripheral blood monocytes (hPBMCs) plated in transwells or layered demonstrated increases in osteoblastogenesis, decreases in osteoclastogenesis, increases in OPG (TNFRSF11B) and decreases in RANKL (TNFSF11) levels. In transwell osteoblasts, MSDK increased pERK1/2 (MAPK1/MAPK3) and RUNX2 levels; decreased ERK5 (MAPK7); and did not affect the expression of NFκB (NFKB1) and β1integrin (ITGB1). In layered osteoblasts, MSDK also decreased expression of the metabolic proteins PPARγ (PPARG) and GLUT4 (SLC2A4). In adipose-derived human MSCs, MSDK induced osteoblastogenesis. These findings provide both clinical and mechanistic support for the use of MSDK for the prevention or treatment of osteopenia, osteoporosis or other bone-related diseases.

Original languageEnglish (US)
Pages (from-to)256-285
Number of pages30
JournalAging
Volume9
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Vitamin K 2
Strontium
Bone Remodeling
Metabolic Bone Diseases
Cholecalciferol
Micronutrients
Osteoclasts
Melatonin
Coculture Techniques
Osteoblasts
Citric Acid
Bone Density
Quality of Life
Bone and Bones
Peroxisome Proliferator-Activated Receptors
Bone Diseases
Femur Neck
Mesenchymal Stromal Cells
Psychometrics
Osteogenesis

Keywords

  • Adipocytes
  • GLUT4
  • Melatonin
  • Osteoblasts
  • Osteoclasts
  • Osteopenia
  • PPARγ

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Cite this

Melatonin-micronutrients Osteopenia Treatment Study (MOTS) : A translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures. / Maria, Sifat; Swanson, Mark H.; Enderby, Larry T.; D'Amico, Frank; Enderby, Brianna; Samsonraj, Rebekah M.; Dudakovic, Amel; van Wijnen, Andre J; Witt-Enderby, Paula A.

In: Aging, Vol. 9, No. 1, 2017, p. 256-285.

Research output: Contribution to journalArticle

@article{f8b0f47294bc4eda8fc7896a4d5baaad,
title = "Melatonin-micronutrients Osteopenia Treatment Study (MOTS): A translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures",
abstract = "This one-year double blind randomized control trial assessed the effects of nightly melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7; MSDK) on bone mineral density (BMD) and quality of life (QOL) in postmenopausal osteopenic women (ages 49-75). Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3{\%}) and left femoral neck (2.2{\%}), with an upward trend for total left hip (p=0.069). MSDK increased serum P1NP levels and reduced bone turnover (CTx:P1NP). Psychometric analyses indicated that mood and sleep quality improved for the MSDK group. MSDK-exposed human mesenchymal stem cells (hMSCs) and human peripheral blood monocytes (hPBMCs) plated in transwells or layered demonstrated increases in osteoblastogenesis, decreases in osteoclastogenesis, increases in OPG (TNFRSF11B) and decreases in RANKL (TNFSF11) levels. In transwell osteoblasts, MSDK increased pERK1/2 (MAPK1/MAPK3) and RUNX2 levels; decreased ERK5 (MAPK7); and did not affect the expression of NFκB (NFKB1) and β1integrin (ITGB1). In layered osteoblasts, MSDK also decreased expression of the metabolic proteins PPARγ (PPARG) and GLUT4 (SLC2A4). In adipose-derived human MSCs, MSDK induced osteoblastogenesis. These findings provide both clinical and mechanistic support for the use of MSDK for the prevention or treatment of osteopenia, osteoporosis or other bone-related diseases.",
keywords = "Adipocytes, GLUT4, Melatonin, Osteoblasts, Osteoclasts, Osteopenia, PPARγ",
author = "Sifat Maria and Swanson, {Mark H.} and Enderby, {Larry T.} and Frank D'Amico and Brianna Enderby and Samsonraj, {Rebekah M.} and Amel Dudakovic and {van Wijnen}, {Andre J} and Witt-Enderby, {Paula A.}",
year = "2017",
doi = "10.18632/aging.101158",
language = "English (US)",
volume = "9",
pages = "256--285",
journal = "Aging",
issn = "1945-4589",
publisher = "US Administration on Aging",
number = "1",

}

TY - JOUR

T1 - Melatonin-micronutrients Osteopenia Treatment Study (MOTS)

T2 - A translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures

AU - Maria, Sifat

AU - Swanson, Mark H.

AU - Enderby, Larry T.

AU - D'Amico, Frank

AU - Enderby, Brianna

AU - Samsonraj, Rebekah M.

AU - Dudakovic, Amel

AU - van Wijnen, Andre J

AU - Witt-Enderby, Paula A.

PY - 2017

Y1 - 2017

N2 - This one-year double blind randomized control trial assessed the effects of nightly melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7; MSDK) on bone mineral density (BMD) and quality of life (QOL) in postmenopausal osteopenic women (ages 49-75). Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3%) and left femoral neck (2.2%), with an upward trend for total left hip (p=0.069). MSDK increased serum P1NP levels and reduced bone turnover (CTx:P1NP). Psychometric analyses indicated that mood and sleep quality improved for the MSDK group. MSDK-exposed human mesenchymal stem cells (hMSCs) and human peripheral blood monocytes (hPBMCs) plated in transwells or layered demonstrated increases in osteoblastogenesis, decreases in osteoclastogenesis, increases in OPG (TNFRSF11B) and decreases in RANKL (TNFSF11) levels. In transwell osteoblasts, MSDK increased pERK1/2 (MAPK1/MAPK3) and RUNX2 levels; decreased ERK5 (MAPK7); and did not affect the expression of NFκB (NFKB1) and β1integrin (ITGB1). In layered osteoblasts, MSDK also decreased expression of the metabolic proteins PPARγ (PPARG) and GLUT4 (SLC2A4). In adipose-derived human MSCs, MSDK induced osteoblastogenesis. These findings provide both clinical and mechanistic support for the use of MSDK for the prevention or treatment of osteopenia, osteoporosis or other bone-related diseases.

AB - This one-year double blind randomized control trial assessed the effects of nightly melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7; MSDK) on bone mineral density (BMD) and quality of life (QOL) in postmenopausal osteopenic women (ages 49-75). Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3%) and left femoral neck (2.2%), with an upward trend for total left hip (p=0.069). MSDK increased serum P1NP levels and reduced bone turnover (CTx:P1NP). Psychometric analyses indicated that mood and sleep quality improved for the MSDK group. MSDK-exposed human mesenchymal stem cells (hMSCs) and human peripheral blood monocytes (hPBMCs) plated in transwells or layered demonstrated increases in osteoblastogenesis, decreases in osteoclastogenesis, increases in OPG (TNFRSF11B) and decreases in RANKL (TNFSF11) levels. In transwell osteoblasts, MSDK increased pERK1/2 (MAPK1/MAPK3) and RUNX2 levels; decreased ERK5 (MAPK7); and did not affect the expression of NFκB (NFKB1) and β1integrin (ITGB1). In layered osteoblasts, MSDK also decreased expression of the metabolic proteins PPARγ (PPARG) and GLUT4 (SLC2A4). In adipose-derived human MSCs, MSDK induced osteoblastogenesis. These findings provide both clinical and mechanistic support for the use of MSDK for the prevention or treatment of osteopenia, osteoporosis or other bone-related diseases.

KW - Adipocytes

KW - GLUT4

KW - Melatonin

KW - Osteoblasts

KW - Osteoclasts

KW - Osteopenia

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=85013427972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013427972&partnerID=8YFLogxK

U2 - 10.18632/aging.101158

DO - 10.18632/aging.101158

M3 - Article

VL - 9

SP - 256

EP - 285

JO - Aging

JF - Aging

SN - 1945-4589

IS - 1

ER -